700 - The Pros, Cons, and Unknowns of Ozempic
Public Health On Call - A podcast by The Johns Hopkins Bloomberg School of Public Health
Medications like Ozempic, Wegovy, and Mounjaro show lots of promise for treating obesity but scientists still don’t understand exactly how they work. There’s also a lack of data to show whether these medications are safe to take long term. Dr. Sameer Khan, a Johns Hopkins fellow in gasteroenterology, talks with Dr. Josh Sharfstein about what these medicines are and what they can do, the questions that remain, and why it’s a challenge for clinicians to prescribe them and for patients to actually obtain them. Learn more about another one of our projects, the Expert Insights newsletter: publichealth.jhu.edu/subscribe
